RT Journal Article SR Electronic T1 Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3477 VO 44 IS Suppl 58 A1 Michael Baldwin A1 Gerardo Machnicki A1 Lingling Li A1 Zhijun Wei A1 Tzy-Chyi Yu A1 Kristijan Henry Kahler YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P3477.abstract AB IntroductionOmalizumab (Xolair®) is associated with reductions in health care resource utilisation (HCRU). Less is known about pre-omalizumab patient characteristics. This research investigated the demographic, clinical and HCRU profile of patients before omalizumab initiation.MethodsRetrospective study using US health care claims data (Truven MarketScan®) during 1/1/2006-31/12/2011. Patients were ≥12 years of age, had 1 inpatient or 2 outpatient asthma claims, moderate or severe asthma (NHLBI criteria) and 2 years of enrollment before omalizumab. Age, gender, Charlson Comorbidity Index (CCI) and all-cause HCRU during the 2 years pre-omalizumab initiation were summarized. Trends in HCRU during these two 12-month periods (2 to 1 and 1 to 0 years pre-omalizumab) were compared using McNemar and 2-sided paired t-tests.Results689 patients were included (mean age 46.2 years; 61.1% female, mean CCI[SD]= 0.60[1.02] and 80% with moderate asthma). Increasing HCRU in the year closest to omalizumab initiation was observed relative to two years before: patients hospitalised (10% vs 14.4%), with ER visits (29.6% vs 37.7%) and with urgent care (6.0% vs 8.7%). Mean HCRU for hospitalisations and hospital length of stay (LOS), ER visits and office visits increased closer to omalizumab initiation (percentage increase: 36%-67%). All results were statistically significant (p<0.03). Moderate patients had lower mean HCRU but larger proportional increases.ConclusionAn acceleration of HCRU was identified in the year before omalizumab initiation. This may point to characteristics to identify patients for omalizumab treatment.